Skip to main content
PMC home page
Heart logoLink to Heart
. 1998 Jun;79(6):593–598. doi: 10.1136/hrt.79.6.593

Quality of life in chronic heart failure: cilazapril and captopril versus placebo

C Bulpitt 1, A Fletcher 1, L Dossegger 1, A Neiss 1, T Nielsen 1, S Viergutz 1
PMCID: PMC1728718  PMID: 10078088

Abstract

Objective—To measure quality of life (QOL) in patients with mild to moderate heart failure treated with angiotensin converting enzyme (ACE) inhibitors cilazapril or captopril.
Design—Randomised, double blind, placebo controlled, parallel groups trial.
Subjects—367 patients with New York Heart Association (NYHA) heart failure class II (62%), III (36%) or IV (1%).
Methods—Patients were randomised to receive cilazapril 1 mg daily (n = 191) or captopril 25 mg three times daily (n = 90) for 24 weeks, or placebo for 12 weeks followed by cilazapril 1 mg daily for a further 12 weeks (n = 86). If patients had not responded after four weeks cilazapril was increased to 2.5 mg daily and captopril to 50 mg three times daily. QOL was assessed at baseline, 12, and 24 weeks using the sickness impact profile (SIP), the profile of mood states (POMS), the Mahler index of dyspnoea-fatigue, and a health status index (HSI).
Results—The physical dimension of the SIP averaged 7 units at baseline and improved after 12 weeks by 2.24 units in the cilazapril group, 2.38 units in the captopril group, and 1.51 units in the placebo group. The difference between drug and placebo was therefore 0.73 units (95% CI −0.86 to 2.32) for cilazapril, and 0.87 units (95% CI −0.96 to 2.70) for captopril, with small non-significant effect sizes (a statistical method for estimating the importance of a treatment related change) of 0.12 and 0.14. Similar results were observed for the total POMS and HSI scores. Although QOL improved more on the ACE inhibitors than on placebo, the effect sizes were not significant (⩽ 0.26).
Conclusions—Improvements in QOL in mild to moderate heart failure were small when treated with cilazapril or captopril compared with placebo.

 Keywords: congestive heart failure;  quality of life;  randomised controlled trial;  cilazapril;  captopril;  ACE inhibitors

Full Text

The Full Text of this article is available as a PDF (123.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baligadoo S. J., Subratty H., Manraz M., Tarral A., Maiti D., Murday M. Effects of enoximone on quality of life. Int J Cardiol. 1990 Jul;28 (Suppl 1):S29–S32. doi: 10.1016/0167-5273(90)90148-x. [DOI] [PubMed] [Google Scholar]
  2. Bergner M., Bobbitt R. A., Carter W. B., Gilson B. S. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981 Aug;19(8):787–805. doi: 10.1097/00005650-198108000-00001. [DOI] [PubMed] [Google Scholar]
  3. Blackwood R., Mayou R. A., Garnham J. C., Armstrong C., Bryant B. Exercise capacity and quality of life in the treatment of heart failure. Clin Pharmacol Ther. 1990 Sep;48(3):325–332. doi: 10.1038/clpt.1990.156. [DOI] [PubMed] [Google Scholar]
  4. Bulpitt C. J., Fletcher A. E. Measurement of the quality of life in congestive heart failure--influence of drug therapy. Cardiovasc Drugs Ther. 1988 Nov;2 (Suppl 1):419–424. [PubMed] [Google Scholar]
  5. Bulpitt C. J., Fletcher A. E. The measurement of quality of life in hypertensive patients: a practical approach. Br J Clin Pharmacol. 1990 Sep;30(3):353–364. doi: 10.1111/j.1365-2125.1990.tb03784.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  7. Croog S. H., Levine S., Testa M. A., Brown B., Bulpitt C. J., Jenkins C. D., Klerman G. L., Williams G. H. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986 Jun 26;314(26):1657–1664. doi: 10.1056/NEJM198606263142602. [DOI] [PubMed] [Google Scholar]
  8. Feinstein A. R., Fisher M. B., Pigeon J. G. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol. 1989 Jul 1;64(1):50–55. doi: 10.1016/0002-9149(89)90652-8. [DOI] [PubMed] [Google Scholar]
  9. Feinstein A. R., Fisher M. B., Pigeon J. G. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol. 1989 Jul 1;64(1):50–55. doi: 10.1016/0002-9149(89)90652-8. [DOI] [PubMed] [Google Scholar]
  10. Fletcher A. E., Bulpitt C. J., Chase D. M., Collins W. C., Furberg C. D., Goggin T. K., Hewett A. J., Neiss A. M. Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine. Hypertension. 1992 Jun;19(6 Pt 1):499–507. doi: 10.1161/01.hyp.19.6.499. [DOI] [PubMed] [Google Scholar]
  11. Fletcher A. Captopril, enalapril, and quality of life. N Engl J Med. 1993 Aug 12;329(7):505–507. [PubMed] [Google Scholar]
  12. Fletcher A., McLoone P., Bulpitt C. Quality of life on angina therapy: a randomised controlled trial of transdermal glyceryl trinitrate against placebo. Lancet. 1988 Jul 2;2(8601):4–8. doi: 10.1016/s0140-6736(88)92942-x. [DOI] [PubMed] [Google Scholar]
  13. Fletcher A. Quality-of-life measurements in the evaluation of treatment: proposed guidelines. Br J Clin Pharmacol. 1995 Mar;39(3):217–222. doi: 10.1111/j.1365-2125.1995.tb04439.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Giles T. D., Fisher M. B., Rush J. E. Lisinopril and captopril in the treatment of heart failure in older patients. Comparison of a long- and short-acting angiotensin-converting enzyme inhibitor. Am J Med. 1988 Sep 23;85(3B):44–47. doi: 10.1016/0002-9343(88)90350-6. [DOI] [PubMed] [Google Scholar]
  15. Kazis L. E., Anderson J. J., Meenan R. F. Effect sizes for interpreting changes in health status. Med Care. 1989 Mar;27(3 Suppl):S178–S189. doi: 10.1097/00005650-198903001-00015. [DOI] [PubMed] [Google Scholar]
  16. Kubo S. H., Gollub S., Bourge R., Rahko P., Cobb F., Jessup M., Brozena S., Brodsky M., Kirlin P., Shanes J. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation. 1992 Mar;85(3):942–949. doi: 10.1161/01.cir.85.3.942. [DOI] [PubMed] [Google Scholar]
  17. Larsen J., Sykulski R., Jensen G., Dössegger L., Trimarco B., Moccetti T., Glogar D., Schelling A., Bosma A. H. Adaptive changes in the acute haemodynamic effects of cilazapril during chronic treatment. Comparison with long-term clinical effect. Eur J Clin Pharmacol. 1996;50(6):433–441. doi: 10.1007/s002280050137. [DOI] [PubMed] [Google Scholar]
  18. Mahler D. A., Weinberg D. H., Wells C. K., Feinstein A. R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984 Jun;85(6):751–758. doi: 10.1378/chest.85.6.751. [DOI] [PubMed] [Google Scholar]
  19. O'Brien A. A., Bulpitt C. J. The effects of ACE inhibitors on cognitive function. Drugs Aging. 1995 Mar;6(3):173–180. doi: 10.2165/00002512-199506030-00001. [DOI] [PubMed] [Google Scholar]
  20. Palmer A. J., Fletcher A. E., Rudge P. J., Andrews C. D., Callaghan T. S., Bulpitt C. J. Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial. J Hypertens. 1992 Nov;10(11):1409–1416. doi: 10.1097/00004872-199211000-00014. [DOI] [PubMed] [Google Scholar]
  21. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  22. Sharpe D. N., Douglas J. E., Coxon R. J., Long B. Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet. 1980 Nov 29;2(8205):1154–1157. doi: 10.1016/s0140-6736(80)92593-3. [DOI] [PubMed] [Google Scholar]
  23. Steiner S. S., Friedhoff A. J., Wilson B. L., Wecker J. R., Santo J. P. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens. 1990 Jun;4(3):217–225. [PubMed] [Google Scholar]
  24. Testa M. A., Anderson R. B., Nackley J. F., Hollenberg N. K. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group. N Engl J Med. 1993 Apr 1;328(13):907–913. doi: 10.1056/NEJM199304013281302. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES